Abstract: A moisturizing product and process designed to let a user quickly and easily rehydrate and moisturize the skin at their convenience, at anytime and any place. The fomulas are a combination of purified water, with a soluble collagen and other products to be applied to treat dry skin to slow the damaging effect of sun, wind, polutents and toxins. Further, the solution of the formula has a Deionized Water and soluble collagen in combination with other additives is applied to the skin by means of a spray in a very fine mist. When the formula reaches the skin it begins to rehydrate the cells of the skin by binding the water to the skin with the collagen in the formula. The cells of the skin exposed to a harsh drying environment are replenished and rehydrated by the fine spray mist.

Abstract: A therapeutic method for treating wounds by dressing the wound with a biocompatible biodegradable collagen tissue product and applying Low Intensity Direct Current (LIDC) to the product. The devices of the invention include biocompatible biodegradable collagen tissue products having means for the application of LIDC to the dressed wound.

Abstract: A therapeutic method for treating pressure ulcers like decubitus ulcers with biodegradable collagen flake compositions and with biodegradable collagen sponge or sponge-like compositions. The products of the invention includes biodegradable collagen flake compositions and biodegradable collagen sponge or sponge-like compositions. The products are useful for medical applications, like skin reconstruction, treatment of wounds, especially deep wounds, also in connection with surgery, including cosmetic surgery. The invention also deals with biocompatible synthetic resin sponge or sponge-like and flake products for medical and similar applications. The invention contemplates the treatment of human and animal species.

Abstract: A method for producing an ossein hydroxyapatite compound from bones or fetal and young animals is described. The compound so produced stimulates chondrocytes and osteoblasts and is useful in the treatment of osteoarthritis, osteoporosis, bone and cartilage defects, and in the healing of bone fractures.

Abstract: Chemically-modified collagen is prepared by reacting native collagen with a di or tri-carboxylic acid halide, di or tri-sulfonyl halide, di or tri-anhydride, or di or tri-reactive active ester coupling agent. The reaction is done in a controlled manner so that the degree of cross-linking is limited. Any remaining lysine epsilon amino groups present in the coupled collagen product may be converted to ureido, .beta.-malicamino carboxyamido or sulfonamido groups by isocyanate, epoxy succinic acid, acid halide, anhydride, sulfonyl halide or active ester aminemodifying agents. The resultant soluble product when dissolved in a physiological buffer provides a viscoelastic solution having therapeutic application in a variety of surgical procedures, particularly in ophthalmic surgery. This viscoelastic solution "melts," i.e., exhibits a dramatic loss of viscosity, when subjected to temperatures of between 32.degree. and 48.degree. C.

Abstract: Aqueous suspensions of fibrillar atelopeptide collagen and osteogenic factor are effective injectable preparations for the repair of bone defects.

Abstract: Chemically-modified collagen is prepared by reacting native collagen with a di or tri-carboxylic acid halide, di or tri-sulfonyl halide, di or tri-anhydride, or di or tri-reative active ester coupling agent. The reaction is done in a controlled manner so that the degree of cross-linking is limited. Any remaining lysine epsilon amino groups present in the coupled collagen product may be converted to carboxyamido or sulfonamido groups by acid halide, anhydride, sulfonyl halide or active ester amine-modifying agents. The resultant product when dissolved in a physiological buffer provides a viscoelastic solution having therapeutic application in a variety of surgical procedures, particularly in ophthalmic surgery. This viscoelastic solution "melts," i.e., exhibits a dramatic loss of viscosity, when subjected to temperatures of between 32.degree. and 48.degree. C.

Abstract: A method for preparing a sustained release formulation utilizing collagen and/or gelatin as a carrier, which comprises the steps:(i) preparing a uniform and high concentrated mixture with respect to the collagen and/or gelatin by blending an active ingredient, said collagen and/or gelatin, and water or an admixture consisting of water and a hydrophilic organic solvent under one of the conditions selected from:(A) the pH of the mixture is kept below 5 and the salt concentration of the mixture is retained below fiber-forming concentration;(B) chemically modified collagen and/or gelatin is employed; and(C) glucose is added to the mixture;(ii) molding the resultant mixture; and(iii) gradually eliminating the solvent from the molded product.

Abstract: A collagen impregnated synthetic vascular graft including a synthetic vascular graft substrate and cross-linked collagen fibril is formed by depositing an aqueous slurry of collagen fibrils in the lumen of the graft and massaging to insure intimate mixing of the fibrils into the porous structure of the substrate. After massaging, the collagen is dried and cross-linked. Repeated applications and massaging and drying further reduce porosity of the graft.

Abstract: A gel formation for oral administration having improved palatability comprising an effective hypocholesterolaemic amount of a uniform gelled dispersion of(a) between about 8 and about 20 percent by weight of a particulate, pharmaceutically acceptable, sparingly crosslinked non-digestible quaternary ammonium substituted polysytrene anion exchange resin having an average particle size below about 100 microns;(b) between about 4 and about 16 percent by weight of a pharmaceutically acceptable gelatin;(c) between about 0.015 and about 10 percent by weight of a natural or synthetic pharmaceutically acceptable sweetener;(d) between about 0.05 and about 2 percent by weight of a pharmaceutically acceptable organic acidulent;(e) between about 0.05 and about 5 percent by weight of one or more pharmaceutically acceptable flavoring or coloring agents or mixtures thereof; and(f) the remainder water.

Abstract: An antithrombogenic medical material with a remarkable antithrombogenic property and histocompatibility as well as sufficient physical strength, formed by fixing a heparinized collagen to a synthetic polymer material is provided. And a method of preparing an antithrombogenic medical material is provided, wherein a synthetic polymer material is subjected to a coating or impregnating treatment with a collagen-containing solution, followed by heparinization of the collagen, and the heparinized collagen is fixed to the synthetic polymer material. This method allows manufacturing of antithrombogenic medical material with ease.

Abstract: A proteinaceous emulsifier can be obtained by reacting an amino acid ester with a hydrophilic protein in the presence of an endopeptidase to form decomposition products of the hydrophilic protein having a carboxyl end group joined to the amino group of the amino acid ester by amide linkage.This proteinaceous emulsifier has a typical surfactant structure in which a hydrophobic portion consisting of the amino acid ester is attached to the rear end of a hydrophilic portion consisting of the protein, and is characterized by causing little irritation to the skin, exhibiting strong emulsifying power and possessing moisture retention properties. Thus, it is very suitable for use as an emulsifier in various cosmetics such as creams, milky lotions and the like.

Abstract: Inflammation, acute and/or chronic, is treated with a CIF (TGF-.beta.). The CIF may be administered locally or symstemically, depending upon the indication, and does not require coadministraion of activator or cofactor for efficacy.

Abstract: Agents for the treatment of arthroses contain peptides soluble in cold water, more specifically those from the group of hydrolyzed collagens. The peptides soluble in cold water are used for the treatment of arthroses and for the preparation of agents for the treatment of arthroses, respectively.

Abstract: Injectable aqueous suspensions of biomaterials, such as cross-linked collagen, that contain a biocompatible fluid lubricant, such as glycogen or maltose, are disclosed. The inclusion of the lubricant significantly improves the intrusion of the suspension into soft tissue.

Abstract: A composition for use in bone repair, in particular, in onlay procedures, which comprises calcium phosphate mineral particles in admixture with atelopeptide reconstituted fibrillar collagen preparations is disclosed. This composition is non-immunogenic and encourages the fusion of host bone with new bone growth through the implant. Additional processes for curing the implant to improve its compressive strength include heat curing, maturation, and cross-linking.

Abstract: The present invention relates to a composition consisting of an association of collagen with an antiseptic and/or antiinflammatory active principle, the process for its preparation and its use for the production of a pharmaceutical composition.The pharmaceutical composition according to the invention comprises collagen as the vehicle and at least one antiseptic and/or inflammatory substance as the active principle.Application to the topical treatment of periodontal complaints.

Abstract: A method of repairing bone defects by use of suspensions containing purified atelopeptide, reconstituted, fibrillar skin collagen or bone collagen powder or mixtures thereof is disclosed. The suspensions provide matrices for conductive growth of bone into the defect. The skin collagen may also be lyophilized and used in the form of mats.

Abstract: An improved wetting solution for contact lenses is disclosed. The solution contains collagen as a wetting agent and preferably a biguanide as a preservative.

Abstract: Cosmetic preparations comprising water soluble fatty acid amide derivatives of hydrolyzed collagen are found to have a substantial degree of permeability to the stratum corneum of human skin and to be effective in improving skin texture, moisture retention and minimizing wrinkles.

Abstract: An improved wetting solution for contact lenses is disclosed. The solution contains gelatin as a wetting agent in an amount less than 1% by weight of the solution so that the viscosity of the solution is substantially less than 15 CPS at 25.degree. C. The solution may also contain a biguanide as a preservative.

Abstract: A solid sustained-release preparation in the form of a needle-like or bar-like shape, which consists essentially of an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, preferably collagen, gelatin, and a mixture thereof). The sustained-release preparation can be administered to the body or implanted into the body by injection or an injection-like method and can release the active ingredient at an effective level for a long period of time when administered.

Abstract: A composition which combines autogenic bone marrow with a suspension of purified atelopeptide reconstituted collagen is used to repair bone defects in mammals.

Abstract: Two proteins that are found in bone and that have in vivo chondrogenic/osteogenic activity in combination with a co-factor are described. Both proteins also were active in combination with EGF in the in vitro TGF-.beta. assay. Each has a molecular weight of approximately 26,000 daltons by SDS-PAGE. Each is reduced to a single polypeptide indicating that the proteins are probably homodimers. One has an N-terminal sequence identical to that of human placenta-derived TGF-.beta. whereas the other has an N-terminal sequence that is different from that of TGF-.beta. derived from human placenta. The two proteins may be purified to homogeneity using RP-HPLC or acetic acid-urea gel electrophoresis.

Abstract: A soft tissue wound healing composition comprising an aqueous mixture of fibrillar collagen, heparin, and undegranulated platelets or platelet releasate. The composition is applied topically to the wound site in conjunction with means to keep it at the site and hydrated or in the form of an occlusive dressing.

Abstract: A biomaterial suitable for use in medical devices which comprises peritoneal tissue, especially animal parietal peritoneum tissue, which has been chemically treated to crosslink the collagen in the tissue.

Abstract: An improved, viscous, transparent, pyrogen-free, isotonic, succinylated atelocollagen solution provides an effective medium for use in viscosurgery and as a replacement for vitreous.

Abstract: This disclosure recognizes the fact that the technology of making vesicles from lecithin and lecithin-like molecules, although well known and highly developed, is associated with problems of instability. It is known that vesicles coalesce, rupture and spill their contents long before the vesicle is used for its intended purpose.It has been discovered and disclosed herein that the deterioration of the vesicle delivery system is due in part to the rupture of the bipolar lipid vesicle membrane by the contents of the core volume or by an external agent. For example, the more detergent-like the properties of the pharmacological agent within the vesicle core volume, the more pronounced will be the attack on the vesicle wall interior. These events in turn will lead to vesicle membrane rupture.

Abstract: Vegetable fatty substance composition for use in cosmetics containing: fatty acid triglycerides 85-94%, fatty acid esters containing 40 carbon atoms 7-14%, vitamins 0.01-1.0%, antioxidant 0.5-1.5% if required.This composition is prepared by malaxing in the heated state, at a temperature not exceeding 50.degree. C., fatty acid triglycerides to which the fatty acid ester is added and after mixing well, the vitamins, and if required, the antioxidant, are added.The fatty substance composition advantageously replaces the animal origin fatty substances in cosmetic compositions.

Abstract: A composite medical article comprising a porous body, a first layer of a medicinal substance and a second layer of a medicinal substance. A method for forming a composite medical article comprising saturating a porous substrate so as to incorporate a first medicinal substance therein, preparing a coating therefor comprising a second medicinal substance with at least a portion thereof in liquid phase, affixing an onlay of the coating to the material by freezing the liquid portion of the coating to the material to form an onlaid composite medical article and drying the article. The medicinal substances may comprise either a hemostatic agent or a medicament.

Abstract: This invention provides a pharmaceutical complex of macromolecules selected from the group consisting of animal and human mesenchymal cells and wherein the macromolecules are fibronectins and procollagens and are produced by the process comprising culturing mesenchymal cells in an appropriate medium to permit the cells to excrete macromolecules into the medium to provide a harvested medium and separating the desired macromolecules from the harvested medium. The complex is used to treat chronic degenerative diseases.

Abstract: Microdroplets of water-insoluble drugs coated with a phospholipid are prepared by sonication. As an example, microdroplets of the general anesthetic methoxyfluorane coated by a unimolecular layer of dimysistoyl phosphatidylcholine are prepared by sonication. The microdroplets so prepared remain stable in physiologically-compatible solution, and are suitable for injection, typically intradermally or intraveneously, into a patient for inducing local anesthesia. These methoxyflurane-containing microdroplets have been demonstrated to cause long-term local anesthesia when injected intradermally, giving duration of anesthesia 28 times longer than with other anesthetics, such as lidocaine and 11 times longer than with bupivacaine. The latter is considered longest acting conventional local anesthetic.

Abstract: Bio-and blood compatible materials are prepared by treating the surface of a substrate to provide reactive primary or secondary amine groups sites which are activated by treatment with a dialdehyde or arylchloride for coupling to a biological in an amount sufficient to provide compatibility. The use of specific substrates, such as a compliant, and elastic material, such as a fabric-elastomer membrane matrix, results in a product having advantageous qualities as a thermal burn dressing. Detailed procedures and various products are described including gloves and sleeves and tubes with or without adhesive to facilitate formation of sheet materials into various forms and products. The products may have small holes provided therein for the rapid passage of accumulated fluid away from the wound or infusion of liquid materials to the wound site.

Abstract: Collagen membranes with desired properties are prepared by using a variety of gel-forming techniques in combination with methods for converting the gels to solid forms. The properties of these membranes or other solid forms may be further altered by cross-linking the collagen preparation either after formation of the membrane or gel, or most preferably by mixing cross-linked collagen with solubilized collagen in the original mixture used to create the gel.

Abstract: Esters of pyridine-2,4- and -2,5-dicarboxylic acid act as inhibitors of proline hydroxylase and lysine hydroxylase and are suitable as fibrosuppressants and immunosuppressants, in particular for the treatment of disturbances of the metabolism of collagen and collagen-like substances and of the biosynthesis of Cl.sub.q.

Abstract: Chemically-modified collagen is prepared by reacting native collagen with a di or tri-carboxylic acid halide, di or tri-sulfonyl halide, di or tri-anhydride, or di or tri-reactive active ester coupling agent. The reaction is done in a controlled manner so that the degree of cross-linking is limited. Any remaining lysine epsilon amino groups present in the coupled collagen product may be converted to carboxyamido or sulfonamido groups by acid halide, anhydride, sulfonyl halide or active ester amine-modifying agents. The resultant product when dissolved in a physiological buffer provides a viscoelastic solution having therapeutic application in a variety of surgical procedures, particularly in ophthalmic surgery. This viscoelastic solution "melts," i.e., exhibits a dramatic loss of viscosity, when subjected to temperatures of between 32.degree. and 48.degree. C.

Abstract: A new sustained-release, microencapsulated pharmaceutical composition is disclosed, suitable for oral administration which contains an effective amount of an orally-administered pharmaceutical in granular form wherein the granules are coated by a layer of homogeneous, native collagen to encapsulate the granules. Also disclosed is a method for administering the sustained-release compositions and a process for covering the granulated pharmaceutical with the layer of homogeneous, native collagen.

Abstract: There are disclosed processes for preparing biodegradable collagen-based matrices in sponge or sheet form wherein in one embodiment a collagen-based material including a collagen selected from the group consisting of types I, II and II collagens is freeze dried to form a collagen-based sponge which is contacted with a cross-linking agent selected from the group consisting of a carbodiimide or a succinimidyl active ester to form an intermediate collagen-based matrix which is subsequently subjected to conditions of severe dehydration to form the collagen-based matrix in sponge or sheet form. In another embodiment, a collagen-based sponge or sheet is first subjected to conditions of severe dehydration followed by contacting the thus formed intermediate collagen-based matrix with a carbodiimide crosslinking compound to form the collagen-based matrix in sponge or sheet form.

Abstract: This invention relates to a cosmetic preparation which comprises novel derivatives of solubilized elastin which are fatty acid amides of elastin, and which have been found to permit deeper penetration and a higher percentage absorption of elastin into the stratum corneum of human skin.

Abstract: A process for preparing collagen membranes useful in tissue repair, and wound healing and related membranous implant materials useful in both hard and soft tissue applications is disclosed. The resulting membranes and materials have properties which can be varied as desired to suit intended use. Variation results from altering the precise conditions of formation of the membrane or of related fibers and solids. The process comprises first forming a gel from solubilized collagen, followed by converting the gel into a one-, two- or three-dimensional membranous solid form. This conversion is performed either by applying pressure to the gel, or by disrupting the gel and separating the resulting precipitate for casting.

Abstract: An injectable collagen material composed of reconstituted, mechanically sheared atelopeptide collagen fibers. The material is prepared by passing reconstituted collagen fibers repeatedly through a rigid mesh screen, until a substantial reduction in fiber size and size-heterogeneity is achieved. The mechanically sheared fibers may be further crosslinked to improve implant characteristics.

Abstract: A partially purified proteinaceous bone-inducing factor of 10,000 to 30,000 daltons is described. It is derived from demineralized bovine bone by extraction with a chaotropic agent, gel filtration, cation exchange chromatography using carboxymethyl cellulose at pH 4.8 and gradient elution with NaCl at 10 mM to about 150 mM.

Abstract: A process for the production of an unnative and biologically active bonded collagen fiber sheet from human placentae is described, in which process collagen-containing material from placentae is treated with a neutral salt solution, a solution of citric acid and with pepsin. The degraded collagen material obtained in this manner is, where appropriate, treated with a crosslinking agent. The collagen material produced in this manner is used for producing bonded collagen fiber sheets which can be used, for example, as covering for wounds.

Abstract: Treatment of cellular disorders involving abnormal solid cellular growths involves introduction of cytotoxic reagents dispersed in a physiologically acceptable proteinaceous matrix into the solid cellular growth or area of an existing or removed solid cellular growth. Enhanced effectiveness of the drug is observed, with reduced cytotoxic effects on cells distant from the site of introduction. Other drugs may be included to enhance therapeutic gain and reduce adverse affects to normal tissue.

Abstract: A clear freely pourable base composition for hair conditioner products comprising, in weight percent, from about 0.1 to about six percent of a derivative of ethoxylated/acetylated lanolin; from about 0.1 to about 1.0 percent of an ionic polymer; from about 0.5 to about 1.0 percent hydroxyethyl cellulose; and a solvent selected from the group consisting of purified water and a water-alcohol mixture. Cationic/anionic grooming agents can be added with cellulose derivatives and viscosity modifiers.

Abstract: An improved hemostatic article is made by fusing an onlay of hemostatic agent to a porous body which is already impregnated with the same or with a different hemostatic agent. The hemostatic agent(s) may comprise a collagen or collagen-like substance which has been modified by rendering the surface charge thereof effectively more positive than prior to modification.

Abstract: A process for preparing collagen membranes useful in tissue repair, and wound healing and related membranous implant materials useful in both hard and soft tissue applications is disclosed. The resulting membranes and materials have properties which can be varied as desired to suit intended use. Variation results from altering the precise conditions of formation of the membrane or of related fibers and solids. The process comprises first forming a gel from solubilized collagen, followed by converting the gel into a one-, two- or three-dimensional membranous solid form. This conversion is performed either by applying pressure to the gel, or by disrupting the gel and separating the resulting precipitate for casting.

Abstract: In a method of producing a tissue adhesive based on polysaccharide or on human or animal proteins, a tissue-compatible flat material is impregnated with a solution of fibrinogen and Factor XIII, and lyophilized.

Abstract: An aqueous atelocollagen solution, which can be injected into living bodies as a medical material, has a pH value in the range from about 6.5 to about 8.0 and an osmolality in the range from about 250 to about 320 mOsm/KgH.sub.2 O, and contains a phosphate buffer solution, or glucose and a phosphate buffer solution, as an agent to adjust pH and osmolality within the ranges specified above. This aqueous atelocollagen solution can be prepared by dissolving atelocollagen in an aqueous acidic solution and adding the above-mentioned pH- and osmolality-adjusting agent to the resulting solution in such an amount as to adjust pH and osmolality of the final solution within the ranges mentioned above.

Abstract: A flexible continuous film is comprised of a physical admixture of a polypeptide, a plasticizer and a film-forming flexible polymer. When the film is moistened, the polypeptides exude therefrom.